{"product_id":"merck-swot-analysis","title":"Merck \u0026 Co. SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrengthen Merck Analysis with a Full SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. is a leading global healthcare company with a diverse portfolio in pharmaceuticals and animal health. Still, investors must weigh its pipeline momentum against patent expirations, pricing pressure, and competitive intensity across key therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eNeed a clearer view of Merck's strengths, weaknesses, opportunities, and threats? Purchase the full SWOT analysis to access a professionally written, fully editable report built to support investment review, strategic assessment, and informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Oncology Portfolio led by Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck's oncology portfolio is a powerhouse, largely driven by Keytruda. This immunotherapy has become a cornerstone of cancer treatment, boasting a wide array of approved uses.\u003c\/p\u003e\n\u003cp\u003eIn the second quarter of 2025, Keytruda alone generated $8.0 billion in sales, marking a robust 9% increase. This performance underscores Keytruda's continued dominance and its critical role in Merck's financial success within the oncology sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust and Expanding Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck's pipeline is a significant strength, boasting a robust and expanding portfolio across multiple therapeutic areas. This diversity aims to reduce reliance on any single product.\u003c\/p\u003e\n\u003cp\u003eThe company has strategically focused on developing new growth drivers, particularly in areas like cardiometabolic diseases and respiratory illnesses, alongside its established oncology leadership. This forward-looking approach is key to long-term success.\u003c\/p\u003e\n\u003cp\u003eEvidence of this expansion is compelling: Merck's late-stage pipeline has tripled since 2021. The company anticipates that these new growth drivers could represent a commercial opportunity exceeding $50 billion by the mid-2030s, highlighting substantial future revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Presence in Animal Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's Animal Health division is a significant powerhouse, showcasing robust growth. In the second quarter of 2025, this segment achieved an impressive 11% sales increase, reaching $1.6 billion.\u003c\/p\u003e\n\u003cp\u003eThis strong performance is fueled by a rising demand for livestock products, a key market for Merck. The strategic acquisition of Elanco's aqua business further bolsters this division, diversifying its revenue and solidifying its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. demonstrates a robust commitment to Research and Development, consistently allocating substantial resources to the discovery and advancement of novel healthcare solutions. This dedication is evident in their pipeline, which is strengthened through both internal innovation and strategic external collaborations, including recent licensing deals and acquisitions designed to enhance their therapeutic offerings.\u003c\/p\u003e\n\u003cp\u003eThe company's R\u0026amp;D strategy focuses on key areas of unmet medical need, driving progress in oncology, vaccines, and other critical therapeutic categories. For instance, in 2023, Merck reported approximately $13.5 billion in R\u0026amp;D expenses, underscoring their significant investment in future growth and innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSignificant R\u0026amp;D Investment:\u003c\/strong\u003e Merck invested around $13.5 billion in R\u0026amp;D for the fiscal year 2023, highlighting a core strategic priority.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Expansion:\u003c\/strong\u003e The company actively pursues pipeline growth through internal discovery efforts and strategic external partnerships, including licensing agreements and acquisitions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocus on Key Therapeutic Areas:\u003c\/strong\u003e R\u0026amp;D efforts are concentrated on high-impact areas such as oncology, vaccines, and other critical medical fields.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation-Driven Growth:\u003c\/strong\u003e This commitment to R\u0026amp;D is fundamental to Merck's strategy for developing groundbreaking treatments and maintaining a competitive edge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and Optimization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. is demonstrating a strong commitment to growth through strategic acquisitions, notably the acquisition of Verona Pharma. This move significantly bolsters Merck's presence in the respiratory disease sector, a key therapeutic area. This proactive portfolio expansion is a core strength, positioning the company for future market leadership.\u003c\/p\u003e\n\u003cp\u003eComplementing its acquisition strategy, Merck has launched a substantial optimization initiative. This plan aims to deliver $3.0 billion in annual cost savings by the conclusion of 2027. These generated savings are earmarked for reinvestment into crucial strategic growth areas, further fueling the company's expansion and innovation efforts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Acquisitions:\u003c\/strong\u003e Verona Pharma acquisition enhances respiratory pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOptimization Initiative:\u003c\/strong\u003e Targeting $3.0 billion in annual cost savings by end of 2027.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReinvestment Strategy:\u003c\/strong\u003e Savings will be channeled into strategic growth areas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Giant's Oncology \u0026amp; Animal Health Drive Strong Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's oncology franchise, led by Keytruda, remains a dominant force, with Q2 2025 sales reaching $8.0 billion, an increase of 9%. The company's pipeline is also a significant strength, having tripled its late-stage assets since 2021, with an anticipated commercial opportunity exceeding $50 billion by the mid-2030s.\u003c\/p\u003e\n\u003cp\u003eThe Animal Health division is another key growth driver, achieving $1.6 billion in sales in Q2 2025, up 11%, bolstered by demand for livestock products and strategic acquisitions like Elanco's aqua business.\u003c\/p\u003e\n\u003cp\u003eMerck's commitment to R\u0026amp;D is substantial, with approximately $13.5 billion invested in 2023, focusing on critical areas like oncology and vaccines. Furthermore, strategic acquisitions, such as Verona Pharma, are enhancing its presence in key therapeutic areas like respiratory diseases.\u003c\/p\u003e\n\u003cp\u003eAn ongoing optimization initiative aims to deliver $3.0 billion in annual cost savings by the end of 2027, with these funds slated for reinvestment into strategic growth areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Sales (Billions USD)\u003c\/th\u003e\n\u003cth\u003eYoY Growth\u003c\/th\u003e\n\u003cth\u003eKey Drivers\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology (Keytruda)\u003c\/td\u003e\n\u003ctd\u003e8.0\u003c\/td\u003e\n\u003ctd\u003e9%\u003c\/td\u003e\n\u003ctd\u003eBroad approved indications, continued market penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal Health\u003c\/td\u003e\n\u003ctd\u003e1.6\u003c\/td\u003e\n\u003ctd\u003e11%\u003c\/td\u003e\n\u003ctd\u003eLivestock product demand, Elanco aqua acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Merck \u0026amp; Co.'s internal strengths, such as its robust R\u0026amp;D pipeline and established market presence, alongside external opportunities like emerging markets and potential new drug approvals, while also addressing weaknesses like reliance on key products and threats from competition and regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHelps identify and address Merck's competitive vulnerabilities and external threats, offering a clear path to mitigating potential risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Reliance on Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck's substantial reliance on Keytruda presents a significant weakness. In 2024, Keytruda generated close to half of Merck's total revenue, highlighting its critical importance to the company's financial performance.\u003c\/p\u003e\n\u003cp\u003eThis heavy dependence makes Merck vulnerable, especially with Keytruda's patent expiration looming in 2028. The anticipated arrival of biosimilar competitors post-exclusivity poses a direct threat to its revenue streams and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Sales of Gardasil\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. faced a significant hurdle with its Gardasil vaccine line, as sales plummeted by 55% in the second quarter of 2025. This sharp decline was largely attributed to reduced demand in China and the winding down of a national catch-up immunization initiative in Japan, impacting a key revenue driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChallenges in Specific Geographic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck is encountering significant hurdles in specific geographic territories, notably impacting its Gardasil vaccine sales. In China, elevated channel inventories have led to a suspension of shipments through at least the end of 2025, a critical factor affecting expected revenue streams.\u003c\/p\u003e\n\u003cp\u003eAdding to these regional difficulties, Gardasil is also experiencing slowing revenue growth in Japan. These market-specific challenges highlight the complexities of global pharmaceutical sales and the need for adaptable strategies to navigate diverse economic and regulatory landscapes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Patent Expirations Beyond Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMerck is navigating patent expirations for several significant products beyond its blockbuster cancer drug Keytruda. Januvia, a key diabetes medication, is projected to face generic competition and a substantial drop in sales starting in 2026. This situation highlights a broader challenge: Merck must continually innovate and diversify its product pipeline to counteract the revenue erosion from these upcoming patent cliffs.\u003c\/p\u003e\n\u003cp\u003eThe impact of these patent expirations extends beyond a single product, creating a systemic risk for Merck's revenue streams. For instance, Januvia generated approximately $5.3 billion in sales in 2023, and its patent expiration will create a notable void. This necessitates a proactive strategy to bring new, high-value drugs to market and explore strategic acquisitions to maintain growth and market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eJanuvia's Impending Patent Expiration:\u003c\/strong\u003e Projected to significantly impact sales from 2026 onwards, following Keytruda's own patent considerations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBroader Portfolio Risk:\u003c\/strong\u003e Multiple key products facing patent expiries create a cumulative revenue challenge for Merck.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeed for Continuous Innovation:\u003c\/strong\u003e Merck must accelerate its R\u0026amp;D efforts and bring new blockbuster drugs to market to offset anticipated sales declines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiversification Imperative:\u003c\/strong\u003e Reducing reliance on a few key products through portfolio expansion is crucial for long-term financial stability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential for Regulatory and Pricing Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe pharmaceutical sector is under growing pressure concerning drug pricing and how costs are covered. In the United States, the Inflation Reduction Act (IRA) is set to influence the pricing of key medications, including Merck's blockbuster cancer treatment Keytruda, beginning in 2026. This legislation could significantly impact Merck's financial performance and its ability to invest in new research and development.\u003c\/p\u003e\n\u003cp\u003eThese regulatory shifts present a notable weakness for Merck. The potential for mandated price reductions on high-revenue drugs like Keytruda could directly affect profit margins. For instance, if Keytruda, which generated approximately $25 billion in revenue in 2023, faces price caps under the IRA, it could lead to a substantial decrease in its contribution to Merck's overall earnings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Scrutiny:\u003c\/strong\u003e Increased governmental and public focus on drug affordability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIRA Impact:\u003c\/strong\u003e The Inflation Reduction Act's negotiation provisions could directly affect revenue from key products like Keytruda starting in 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReimbursement Challenges:\u003c\/strong\u003e Evolving policies for how drugs are paid for by insurers and government programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Funding:\u003c\/strong\u003e Potential reduction in profits could limit future investment in R\u0026amp;D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue at Risk: Patent Expirations and Product Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's significant reliance on Keytruda, which accounted for nearly half of its revenue in 2024, creates a substantial vulnerability. This dependence is amplified by Keytruda's patent expiration in 2028, opening the door for biosimilar competition and potential revenue erosion.\u003c\/p\u003e\n\u003cp\u003eThe company is also facing challenges with its Gardasil vaccine, with sales dropping 55% in Q2 2025 due to decreased demand in China and the end of a Japanese immunization initiative. Furthermore, patent expirations for drugs like Januvia, which generated $5.3 billion in 2023, necessitate a constant drive for new product innovation and pipeline diversification.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003e2023 Revenue (approx.)\u003c\/td\u003e\n\u003ctd\u003eKey Risk\u003c\/td\u003e\n\u003ctd\u003eImpact Timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e$25 billion\u003c\/td\u003e\n\u003ctd\u003ePatent Expiration (2028), Biosimilar Competition\u003c\/td\u003e\n\u003ctd\u003ePost-2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanuvia\u003c\/td\u003e\n\u003ctd\u003e$5.3 billion\u003c\/td\u003e\n\u003ctd\u003ePatent Expiration (2026), Generic Competition\u003c\/td\u003e\n\u003ctd\u003eFrom 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil\u003c\/td\u003e\n\u003ctd\u003eN\/A (Significant decline in 2025)\u003c\/td\u003e\n\u003ctd\u003eReduced Demand (China), Program Wind-down (Japan)\u003c\/td\u003e\n\u003ctd\u003eOngoing (2025 onwards)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMerck \u0026amp; Co. SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the same Merck \u0026amp; Co. SWOT analysis document included in your download. The full content is unlocked after payment, giving you a comprehensive understanding of their Strengths, Weaknesses, Opportunities, and Threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversification of Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck has a significant opportunity to broaden its revenue base by venturing beyond its strong oncology portfolio. Exploring growth in areas such as cardiometabolic diseases and respiratory illnesses presents a chance to tap into large and growing markets. For instance, the global cardiometabolic drugs market was valued at approximately $200 billion in 2023 and is projected to expand further.\u003c\/p\u003e\n\u003cp\u003eStrategic investments in research and development, or targeted acquisitions, in these less saturated therapeutic areas can effectively reduce Merck's dependence on its blockbuster drug, Keytruda. This diversification is crucial for ensuring sustained financial performance and mitigating risks associated with the eventual patent expiration of its key products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Expansion and Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck can significantly boost its global footprint by focusing on emerging markets where healthcare demand is rapidly increasing. For instance, in 2024, the global pharmaceutical market in emerging economies was projected to grow at a compound annual growth rate (CAGR) of over 7%, significantly outpacing developed markets.\u003c\/p\u003e\n\u003cp\u003eBy tailoring its product offerings and distribution strategies to meet the specific needs and affordability levels in these regions, Merck can capture substantial market share. This approach is crucial as many emerging economies are investing heavily in healthcare infrastructure and access to medicines, creating fertile ground for expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancements in R\u0026amp;D and Strategic Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's commitment to robust research and development, with significant investments in cutting-edge technologies and digital business models, positions it to discover breakthrough therapies and novel solutions. This continuous innovation is crucial for staying ahead in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003cp\u003eStrategic alliances, like the ongoing collaborations with Taiho Pharmaceutical and Astex Pharmaceuticals, are pivotal in expediting drug development timelines and broadening Merck's therapeutic pipeline. These partnerships leverage external expertise and resources, enhancing the company's capacity for innovation and market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeveraging Animal Health Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck's Animal Health division is poised for significant expansion, fueled by increasing pet ownership and the global demand for safe, efficient food production. This sector consistently demonstrates robust growth, providing a reliable avenue for revenue generation and market penetration.\u003c\/p\u003e\n\u003cp\u003eMerck can further solidify its position by investing in cutting-edge research and development for novel animal therapeutics and vaccines. Strategic acquisitions of innovative animal health companies or technologies will also be crucial to harness emerging market trends and expand its product portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowing Demand:\u003c\/strong\u003e The global animal health market was valued at approximately $60 billion in 2023 and is projected to reach over $80 billion by 2028, driven by increased spending on companion animals and livestock health.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Focus:\u003c\/strong\u003e Merck's pipeline includes advancements in areas like parasiticides and vaccines, aiming to address unmet needs in both companion and food-producing animals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Acquisitions:\u003c\/strong\u003e Past acquisitions, such as the purchase of Elanco's Interceptor Plus, have strengthened Merck's offerings in key therapeutic areas within animal health.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainability and ESG Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck's dedication to Environmental, Social, and Governance (ESG) principles presents a significant opportunity. The company has set ambitious targets, aiming for climate neutrality and increased renewable energy usage. This commitment not only bolsters Merck's public image but also appeals to a growing segment of investors prioritizing sustainability, potentially improving access to capital.\u003c\/p\u003e\n\u003cp\u003eFurthermore, embedding sustainability throughout its operations, from research and development to manufacturing, can unlock operational efficiencies and drive innovation. For instance, by 2023, Merck reported a 20% reduction in Scope 1 and 2 greenhouse gas emissions compared to its 2019 baseline, showcasing tangible progress in its environmental stewardship.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Brand Reputation:\u003c\/strong\u003e Strong ESG performance attracts socially conscious consumers and partners.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestor Attraction:\u003c\/strong\u003e Growing interest from ESG-focused funds, such as those managed by BlackRock, which emphasizes sustainable investing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Efficiencies:\u003c\/strong\u003e Renewable energy adoption and waste reduction can lead to cost savings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Driver:\u003c\/strong\u003e Integrating sustainability into R\u0026amp;D can spur the development of greener products and processes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlocking Future Growth: Diversifying Pharma and Expanding Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck has a substantial opportunity to diversify its revenue streams by expanding beyond its core oncology offerings into high-growth areas like cardiometabolic diseases and respiratory illnesses. The company can also leverage its robust R\u0026amp;D capabilities and strategic partnerships to develop innovative therapies and maintain a competitive edge in the rapidly evolving pharmaceutical landscape.\u003c\/p\u003e\n\u003cp\u003eExpanding into emerging markets offers significant growth potential, given the increasing healthcare demand and infrastructure investments in these regions. Furthermore, Merck's Animal Health division is well-positioned for continued expansion, driven by rising pet ownership and the global need for efficient food production, with the market projected to reach over $80 billion by 2028.\u003c\/p\u003e\n\u003cp\u003eMerck's commitment to ESG principles presents an opportunity to enhance its brand reputation and attract sustainability-focused investors, potentially improving access to capital. By integrating sustainability into its operations, the company can also achieve operational efficiencies and drive innovation in product development.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpportunity Area\u003c\/td\u003e\n\u003ctd\u003eKey Drivers\u003c\/td\u003e\n\u003ctd\u003eMarket Data\/Projections\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic Diversification\u003c\/td\u003e\n\u003ctd\u003eUntapped markets in cardiometabolic and respiratory diseases\u003c\/td\u003e\n\u003ctd\u003eCardiometabolic drugs market valued at ~$200 billion (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging Markets Expansion\u003c\/td\u003e\n\u003ctd\u003eIncreasing healthcare demand and investment\u003c\/td\u003e\n\u003ctd\u003eEmerging economies pharma market CAGR \u0026gt;7% (2024 projection)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal Health Growth\u003c\/td\u003e\n\u003ctd\u003eIncreased pet ownership, demand for food production\u003c\/td\u003e\n\u003ctd\u003eAnimal Health market to reach \u0026gt;$80 billion by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESG Integration\u003c\/td\u003e\n\u003ctd\u003eInvestor focus on sustainability, operational efficiencies\u003c\/td\u003e\n\u003ctd\u003e20% reduction in Scope 1 \u0026amp; 2 GHG emissions (vs. 2019 baseline) by 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeytruda Patent Expiration and Biosimilar Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe most significant threat facing Merck \u0026amp; Co. is the impending patent expiration of its blockbuster drug, Keytruda, in the United States in 2028. This event is poised to usher in biosimilar competition, which could drastically impact Merck's revenue streams.\u003c\/p\u003e\n\u003cp\u003eKeytruda has been a major growth driver for Merck, consistently contributing billions in sales annually. For instance, in 2023, Keytruda generated approximately $25 billion in revenue. The introduction of biosimilars, which are highly similar versions of biologic drugs, typically leads to significant price erosion and a substantial decrease in market share for the originator product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in the Pharmaceutical Industry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe pharmaceutical landscape is fiercely competitive, with giants and emerging players constantly innovating. Merck faces significant pressure from rivals like Pfizer, Johnson \u0026amp; Johnson, and Roche, all actively pursuing advancements in oncology, immunology, and other critical areas. For instance, in 2024, the global pharmaceutical market was valued at over $1.5 trillion, highlighting the intense battle for revenue and market share.\u003c\/p\u003e\n\u003cp\u003eNew blockbuster drug approvals by competitors pose a direct threat to Merck's established products. The rapid development of novel therapies, particularly in areas where Merck has a strong presence like cancer treatment, can quickly erode market dominance. This dynamic means Merck must continuously invest in R\u0026amp;D to maintain its competitive edge and counter potential market share erosion from breakthrough innovations elsewhere.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Healthcare Policy Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolving regulatory landscapes, particularly concerning drug pricing and market access in key markets like the United States, present a significant challenge for Merck \u0026amp; Co. For instance, the Inflation Reduction Act of 2022, which allows Medicare to negotiate prices for certain high-cost drugs, could directly impact Merck's revenue streams from its blockbuster products.\u003c\/p\u003e\n\u003cp\u003eThe potential for increased scrutiny and changes in healthcare policy worldwide could also affect the profitability and availability of Merck's pharmaceutical and vaccine offerings. This dynamic environment necessitates continuous adaptation and strategic planning to navigate potential impacts on sales and research and development investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical and Macroeconomic Instability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. faces significant risks from global geopolitical and macroeconomic instability. Heightened international tensions, such as ongoing conflicts and trade disputes, can disrupt supply chains critical for pharmaceutical manufacturing and distribution. For instance, the ongoing geopolitical shifts in Eastern Europe and the Middle East in 2024 continue to pose risks to global logistics and raw material sourcing.\u003c\/p\u003e\n\u003cp\u003eCurrency fluctuations also present a challenge. As a global company, Merck's reported earnings can be significantly impacted by changes in exchange rates. In 2024, the strengthening US dollar against several major currencies could translate into lower reported revenues when foreign earnings are converted back to dollars. Economic downturns or the imposition of new trade barriers in key markets, like potential protectionist measures in emerging economies, could also dampen sales and profitability for Merck's diverse product portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSupply Chain Vulnerability:\u003c\/strong\u003e Geopolitical events can directly impact the availability and cost of raw materials and finished goods, affecting production schedules and potentially leading to shortages.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCurrency Exchange Rate Volatility:\u003c\/strong\u003e Fluctuations in foreign exchange rates in 2024 have a direct impact on Merck's international revenue and profit translation, potentially reducing reported financial performance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access and Trade Barriers:\u003c\/strong\u003e Increased protectionism or economic slowdowns in major markets could limit market access for Merck's pharmaceuticals and reduce overall sales volume and pricing power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Failures and Pipeline Setbacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMerck's reliance on research and development (R\u0026amp;D) inherently carries significant risk; a substantial percentage of drug candidates often fail to gain regulatory approval or achieve market success. This means that future growth could be jeopardized if key pipeline drugs falter in clinical trials or fail to capture market share, especially as existing blockbuster drugs face patent expirations.\u003c\/p\u003e\n\u003cp\u003eFor instance, the pharmaceutical industry generally sees high attrition rates, with estimates suggesting that only about 10% of drugs entering clinical trials ultimately receive FDA approval. Merck's own pipeline, while robust, is not immune to these challenges. A notable example from recent years includes the discontinuation of certain investigational compounds, underscoring the unpredictable nature of drug development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh R\u0026amp;D Attrition:\u003c\/strong\u003e Pharmaceutical R\u0026amp;D typically experiences a failure rate of over 90% for drugs entering clinical trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Dependency:\u003c\/strong\u003e Future revenue streams are heavily reliant on the successful progression and commercialization of current pipeline assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBlockbuster Risk:\u003c\/strong\u003e Failure to replace revenue from soon-to-expire patents with new, high-selling drugs poses a significant threat to sustained growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Trial Setbacks:\u003c\/strong\u003e Unfavorable results in Phase II or Phase III trials can lead to costly delays or outright abandonment of promising candidates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Giants Face Patent Cliffs, Regulatory Hurdles, and Market Battles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck faces intense competition from rivals like Pfizer and Roche, with the global pharmaceutical market exceeding $1.5 trillion in 2024, making market share gains challenging. The looming patent expiration of Keytruda in the US in 2028 is a major threat, as biosimilar competition typically leads to significant price erosion, impacting its $25 billion 2023 revenue. Furthermore, evolving regulations, such as the Inflation Reduction Act of 2022 allowing Medicare drug price negotiations, could directly reduce revenue from key products.\u003c\/p\u003e\n\u003cp\u003eGeopolitical instability and currency fluctuations also pose risks. In 2024, supply chain disruptions due to global tensions and the strengthening US dollar against other currencies could negatively impact reported earnings. Additionally, increased protectionism or economic slowdowns in key markets could limit market access and reduce pricing power for Merck's portfolio.\u003c\/p\u003e\n\u003cp\u003eThe inherent risk in pharmaceutical R\u0026amp;D, with over 90% of drugs failing in clinical trials, presents a threat to Merck's future growth. Failure to successfully commercialize pipeline assets to offset patent expirations could significantly jeopardize sustained growth. For instance, clinical trial setbacks can cause costly delays or abandonment of promising drug candidates.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53680866394454,"sku":"merck-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/merck-swot-analysis.webp?v=1778891674","url":"https:\/\/balancedscorecardexamples.com\/products\/merck-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}